The $6 Billion Debt Wall: Which Cannabis Companies Are About to Collapse

There is a cliff coming for the cannabis industry, and most of the people who work in it have no idea how close they're standing to the edge. By the end of 2026, approximately $6 billion in cannabis-sector debt comes due. Of that, roughly $3.4 billion is owed by just five multistate operators. The companies have to either refinance, restructure, or default. Given the cost of capital in cannabis right now and the operating performance of the borrowers in question, options two and three are looking increasingly likely.

This is the story Wall Street started whispering about in late 2025 and that finally broke into the trade press in early 2026. It's bigger than any single bankruptcy. It's an industry-wide reckoning that is going to redraw the competitive map of American cannabis.

How Cannabis Got Buried in Expensive Debt

To understand why the debt wall exists, you have to understand the financing constraints that built it.

Federally illegal businesses cannot access traditional bank credit. They cannot list on the New York Stock Exchange or NASDAQ. They cannot borrow from the SBA. They cannot use FedEx or USPS. The federal financial system is, by design and statute, closed to them.

What they have instead is a patchwork of capital sources: private equity funds with cannabis-specific mandates, hedge funds willing to take cannabis exposure for premium yields, sale-leaseback REITs like Innovative Industrial Properties, Canadian capital markets where listing is permitted, convertible note structures that defer the question of equity versus debt, and a small handful of specialty lenders charging rates that would be considered usurious in conventional industries.

The result was a debt market where coupon rates of 12, 15, even 18 percent were normal. Companies that would have paid 4 or 5 percent in any other industry borrowed at multiples of that. The implicit assumption was that federal reform — banking access, rescheduling, full legalization — would arrive before maturity dates and dramatically lower refinancing costs. That bet has now run out of time.

The $3.4 Billion in Five Companies

Of the $6 billion maturing by end of 2026, the five largest borrowers — all MSOs — account for $3.4 billion. Industry analyst reports and SEC filings allow us to identify the major exposures.

Curaleaf carries the largest combined debt load, with senior notes and other instruments rolling over across 2025 and 2026. The company has been actively negotiating refinancing terms but faces a hostile capital market.

Verano, Cresco Labs, Trulieve, and Ascend Wellness round out the top five, each carrying combined obligations in the high-hundreds of millions. Some of these are sale-leaseback rent obligations rather than traditional debt, but functionally they're equivalent: fixed payments that have to be made or the company loses access to the underlying real estate.

Outside the top five, the picture gets worse. PharmaCann defaulted on $29 million in annual rent obligations to IIPR in 2025. 4Front Ventures defaulted on $18 million the same year. Multiple smaller operators have entered receivership. The Cannabist Co. filed for bankruptcy protection in March 2026 with $270 million owed across lenders and the IRS.

Why Refinancing Won't Save Most of Them

The natural assumption when reading about a debt wall is that the affected companies will simply refinance. New debt replaces old debt at slightly different terms, and life goes on. That's how it works in normal industries.

It's not how it's working in cannabis.

The lenders who provided the original capital are now demanding either much higher coupons (sometimes 20 percent or more), much shorter maturities, much tighter covenants, or some combination of all three. New lenders willing to step in are scarce, and the ones who exist are pricing the same way. The cost of refinancing in cannabis right now is so high that for many borrowers, the math doesn't work. The debt service alone would consume more cash than the company generates from operations.

In normal industries, when refinancing terms get this punishing, equity holders dilute themselves to bring in new capital. But cannabis equity has been crushed for three years. Most public MSO stocks trade at fractions of their 2021 highs. Issuing new shares at depressed prices means handing existing shareholders catastrophic dilution. Boards are reluctant to do it. Management teams are politically incentivized to delay it. And so the debt sits, the maturity dates approach, and the choices narrow.

The Bankruptcy Cascade

The Cannabist filing in March 2026 is the canary. It will not be the last.

When a major MSO files for bankruptcy, the consequences ripple in three directions. First, lenders move faster on the next-weakest borrowers, demanding accelerated payments or filing involuntary petitions to protect their positions. Second, sale-leaseback REITs like IIPR — whose tenant base is concentrated among the same MSOs — face additional defaults and write-downs, which depress their stock and impair their ability to fund new deals. Third, distressed asset prices for cannabis licenses, real estate, and operating businesses crater, because the supply of forced sellers far exceeds the supply of qualified buyers.

That third effect is, perversely, the silver lining for whoever has cash. Cannabis assets purchased at distressed prices in 2026 will outperform spectacularly when (and if) federal reform eventually arrives. The buyers in this cycle will be the MSOs of the next era. They will not be the same companies that built the current MSOs.

Strong-balance-sheet operators — and there are a few — are already positioning. Glass House Brands, with comparatively low leverage and California-anchored cultivation, has indicated acquisition appetite. Schwazze in Colorado is positioning to consolidate the regional Rocky Mountain market. A handful of well-capitalized private operators are quietly raising distressed-asset funds.

Who Survives, Who Doesn't

The honest answer is that no one knows for sure. But certain factors separate likely survivors from likely casualties.

Survivors tend to share these traits:

• Debt-to-EBITDA below 4x
• Operations concentrated in fewer states with stronger margins
• Real estate ownership rather than sale-leaseback exposure
• Founder-led management with skin in the game
• Cash on the balance sheet sufficient for at least 12 months of debt service

Casualties tend to share these traits:

• Debt-to-EBITDA above 6x
• Heavy sale-leaseback rent obligations
• Operations spread across many states (which dilutes management focus and complicates restructuring)
• Professional management installed by financial sponsors
• Cash runway under 6 months

By those metrics, several of the top-five borrowers are squarely in the casualty category. Public analyst reports have flagged at least three of the largest MSOs as facing genuine going-concern risk if refinancing terms don't improve.

What This Means for Workers and Communities

Every MSO bankruptcy carries human consequences that don't show up in the financial press. Cultivation workers laid off without notice. Budtenders losing healthcare coverage. Vendors and small suppliers stiffed for invoices already delivered. Local tax revenues collapsing in jurisdictions that became dependent on cannabis tax flows.

In some states, the impact will hit disproportionately on the same communities that legalization promised to lift. Social equity dispensaries that signed supply agreements with MSO cultivators are now at the front of the line of unsecured creditors when those cultivators file. Workforce development programs funded by cannabis tax revenue face cuts when sales decline as operators shutter stores.

The lender litigation that follows each bankruptcy adds another layer. Vendors and small creditors typically recover pennies on the dollar in cannabis bankruptcies, because senior secured debt and tax claims consume most of the available estate. The MSOs got the upside of operating at scale during the good years. The downside, when it arrives, gets distributed across everyone they did business with.

What This Means for Consumers

In the short term, debt wall pressure may actually push prices down as distressed operators dump inventory to generate cash. That's already happening in some markets, where flower prices have fallen by 20–30% over 18 months even as taxes and regulatory costs continue to climb.

In the medium term, consolidation eliminates competition. The companies that survive the cycle will face less competitive pressure, which historically translates to higher prices and reduced product innovation. The Ohio AG's cartel allegations against the existing MSOs hint at how that already plays out. A more concentrated post-collapse industry could be even worse.

In the long term, the question is whether cannabis remains a sector with diverse operators serving local tastes, or whether it consolidates into a small number of national brands operated by financial holding companies. The debt wall is the mechanism by which that question gets answered.

What to Watch Next

A handful of catalysts in the next 6–12 months will determine how the debt wall resolves.

Federal rescheduling progress. A finalized move to Schedule III would dramatically improve cannabis financials by eliminating 280E tax exposure and unlocking institutional capital flows. Even a credible signal of imminent rescheduling would change refinancing terms.

The Cannabist proceedings. As the first major MSO bankruptcy, the case will set precedents on creditor priority, IRS treatment, and asset disposition that future filings will follow.

REIT-tenant negotiations. Watch for additional defaults from IIPR's largest tenants, and watch IIPR's response. Forced sales of leased facilities would accelerate the cascade.

Lender behavior. The shift from "extend and pretend" to active enforcement has begun. The next few quarters will reveal which lenders are willing to take haircuts in restructurings versus pushing borrowers into formal bankruptcy.

The cliff is real. The math is not friendly. Some of the names that defined cannabis in 2024 will not be around in 2027. That's not a prediction. That's just the schedule.

---

Internal links:

• The MSO Cartel: Inside the Price-Fixing Lawsuit →
• The Cannabist Bankruptcy: How a Top MSO Lost Everything →
• The Cannabis Real Estate Bubble →